BioAtla, Inc.
BCAB evidence brief
What we can confirm
What it means
What to watch
Prepared research question
What matters most for BCAB—catalysts, financial risk and supporting evidence?
Traceable citations · Unknowns marked
BioSniper AI · BCAB
BioAtla, Inc. is a clinical-stage biopharmaceutical company developing conditionally active biologics (CABs) for solid tumor cancers, with ongoing Phase 2 trials for mecbotamab vedotin, ozuriftamab vedotin, and evalstotug, and a Phase 1 trial for BA3182.
Key risk: Limited cash runway
BioSniper Score
Based on 4 of 6 signals
Financial data as of Jun 30, 2026.
Tracking 7 pipeline candidates · 5 clinical trials for BioAtla, Inc..
BioAtla, Inc. is a clinical-stage biopharmaceutical company developing conditionally active biologics (CABs) for solid tumor cancers, with ongoing Phase 2 trials for mecbotamab vedotin, ozuriftamab vedotin, and evalstotug, and a Phase 1 trial for BA3182.
- BioAtla is a clinical-stage biopharmaceutical company developing conditionally active biologics (CABs) for solid tumor cancers [sec · filed 2025-04-24].
- The company has ongoing Phase 2 clinical trials for mecbotamab vedotin (BA3011), ozuriftamab vedotin (BA3021), and evalstotug (BA3071), and a Phase 1 trial for BA3182 (CAB-EpCAM x CAB-CD3) [sec_mda · as of 2025-11-13].
- As of 2026-06-30, the company reported cash and equivalents of $1.5M, net income of $0.5M, and negative shareholders' equity of -$36.2M [sec].
- In March 2025, the company implemented a restructuring that included a 30% workforce reduction and a reduction in lease footprint by almost half in June 2025 to lower costs and extend cash runway [sec_mda · as of 2025-11-13].
- Key management includes Jay M. Short, Ph.D. as CEO, Cofounder and Chairman; Richard A. Waldron as CFO; and Eric Sievers, M.D. as CMO [sec · filed 2025-04-24].
What works
- The company's CAB platform aims to target known and validated tumor antigens while reducing on-target, off-tumor toxicity, a key challenge in cancer therapy [sec · filed 2025-04-24].
- Multiple product candidates are in clinical development, including three in Phase 2 trials, indicating a diversified pipeline [sec_mda · as of 2025-11-13].
- The company has taken proactive cost-reduction measures, including a 30% workforce reduction and lease footprint reduction, to extend cash runway [sec_mda · as of 2025-11-13].
What to weigh
- The company has a history of significant operating losses and negative shareholders' equity of -$36.2M as of 2026-06-30 [sec].
- Cash and equivalents are only $1.5M as of 2026-06-30, which may limit the company's ability to fund ongoing operations without additional financing [sec].
- The company faces substantial uncertainty in the regulatory approval process for its product candidates [sec_mda · as of 2025-11-13].
- The restructuring and workforce reduction in 2025 indicate financial strain and potential challenges in advancing the pipeline [sec_mda · as of 2025-11-13].
From the filings
Quoted directly from source documents.
BioAtla is a clinical-stage biopharmaceutical company developing conditionally active biologics for solid tumors.
“We are a clinical-stage biopharmaceutical company developing our novel class of highly specific and selective antibody-based therapeutics for the treatment of solid tumor cancer.”
SEC filings · April 24, 2025
The company has ongoing Phase 2 trials for mecbotamab vedotin, ozuriftamab vedotin, and evalstotug, and a Phase 1 trial for BA3182.
“ongoing Phase 2 clinical trials of mecbotamab vedotin (BA3011), ozuriftamab vedotin (BA3021), evalstotug (BA3071), and our Phase 1 clinical trial of BA3182 (CAB-EpCAM x CAB-CD3)”
SEC MD&A · November 13, 2025
The company implemented a restructuring in March 2025 with a 30% workforce reduction and lease footprint reduction.
“including a restructuring in March 2025 that included a 30% workforce reduction, and a reduction in our lease footprint by almost half in June 2025”
SEC MD&A · November 13, 2025
Risks & what to watch (4)›
Key risks
- Limited cash runway — Cash and equivalents of $1.5M as of 2026-06-30 may be insufficient to fund operations without additional financing [sec].
- Negative shareholders' equity — Shareholders' equity of -$36.2M as of 2026-06-30 indicates accumulated deficits and financial instability [sec].
- Regulatory approval uncertainty — The company faces risks and uncertainties in the regulatory approval process for its product candidates [sec_mda · as of 2025-11-13].
- Dependence on clinical trial success — The company's future depends on successful completion of ongoing Phase 2 and Phase 1 trials [sec_mda · as of 2025-11-13].
What to watch
- Progress and data readouts from Phase 2 trials of mecbotamab vedotin, ozuriftamab vedotin, and evalstotug [sec_mda · as of 2025-11-13].
- Phase 1 trial results for BA3182 (CAB-EpCAM x CAB-CD3) [sec_mda · as of 2025-11-13].
- Ability to secure additional financing given low cash reserves of $1.5M as of 2026-06-30 [sec].
- Impact of the March 2025 restructuring on pipeline advancement and operational efficiency [sec_mda · as of 2025-11-13].
Sources: SEC filings · SEC MD&A · Generated August 29, 2026 · How we verify sources →
Run BioAtla, Inc. through your own thesis
Use the pipeline, catalyst, financial, FDA, and market facts on this page as inputs to a protocol you control.
Your protocol can:
- Turn available BioAtla, Inc. facts into screen rules or deeper checks
- Show cited findings, blockers, and unresolved evidence together
- Save the logic and rerun it as the company evidence changes
Evidence & data
Score breakdownBased on 4 of 6 signals · derived from public data
16.9 months
OCF -$419K · Net income $452K
Lead: Phase 2
7 candidates
No upcoming catalysts tracked
No insider transactions in the last 180 days
Runway
Pipeline
Regulatory
Financials
Institutional Holdings
Source: SEC Form 13F · as of Mar 2026Institutional holders
1
Total value held
$44K
| Holder | Shares | Value |
|---|---|---|
| marshall wace, llp | 277,630 | $44K |
Short Interest
as of May 20, 2026- % of float
- 8.9%
- Days to cover
- 2.9
- Shares short
- 147,268
- Daily short volume
- -
Short percent of float and days-to-cover reflect reported short positioning. Daily short volume is the exchange-reported short share of a single day's trading volume and is noisier. See the most-shorted biotech ranking →
BCAB short interestGovernance
Frequently asked questions
What is the AI investment thesis for BioAtla, Inc.?
BioAtla, Inc. is a clinical-stage biopharmaceutical company developing conditionally active biologics (CABs) for solid tumor cancers, with ongoing Phase 2 trials for mecbotamab vedotin, ozuriftamab vedotin, and evalstotug, and a Phase 1 trial for BA3182.
What is BioAtla, Inc.'s lead drug candidate?
BioAtla, Inc.'s most advanced tracked candidate is ba3182 (Phase 1) for Advanced Adenocarcinoma.
Who is the CEO of BioAtla, Inc.?
Dr. Jay M. Short Ph.D. is the chief executive officer of BioAtla, Inc. (BCAB).
Where is BioAtla, Inc. headquartered?
BioAtla, Inc. (BCAB) is headquartered in San Diego, CA, United States.
What therapeutic areas does BioAtla, Inc. focus on?
BioAtla, Inc. develops therapies across Oncology.
The AI overview and BioSniper Score are neutral, data-derived signals built from public SEC filings, ClinicalTrials.gov and FDA records — not investment advice.